Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma

19 Apr 2020

Abstract excerpt

The tyrosine kinase inhibitor (TKI) sorafenib continues to be the anchor drug in the treatment of advanced stage hepatocellular carcinoma (HCC). Other TKIs as well as immune checkpoint inhibitors (ICIs) have also been approved, however the response rates remain poor and heterogeneous among HCC patients, largely due to antitumor drug resistance. Studies aimed at identifying novel biomarkers and developing new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32371296
DOI: 10.1016/j.drup.2020.100702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinomaPMID 32371296Read ↗

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinomaSemantic proximity Read ↗

Hepatocellular carcinoma: old friends and new tricksSemantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular CarcinomaSemantic proximity Read ↗

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.Semantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Breaking Therapeutic Resistance in Hepatocellular Carcinoma: Systems Biology Deconvolution of the B-cell Microenvironment Identifies PDIA6 as a Novel TargetSemantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinomaSemantic proximity Read ↗

A Novel Immune Classification Reveals Distinct Immune Escape Mechanism and Genomic Alterations: Implications for Immunotherapy in Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.